Previous 10 | Next 10 |
Moha El-Jaw/iStock via Getty Images "Magic mushrooms," LSD, and MDMA, once thought to be purely recreational drugs, are under investigation by many publicly traded companies as potential psychedelic treatments for a range of diseases. An increasing amount of research is demonstrating that the...
ATAI Life Sciences N.V (ATAI), Compass Pathways Plc (CMPS), and Mind Medicine Holdings (MNMD) are 3 stocks that are looking to commercialize psychedelics for medical use. Investors should keep them on their radars as they have massive long-term potential. Norms and regulations in society...
Leading U.S.-Based Psychedelic Healthcare VC Fund Launches with $35 Million Raised to Tackle the Growing Global Mental Health Crisis Palo Santo's Commitment to Help Fund a New Paradigm in Wellbeing PR Newswire CHICAGO , July 15, 2021 /PRNewswire/ -- P ...
adrian825/iStock via Getty Images Psychedelic drug developers started as buys Citi, Credit Suisse, Canaccord Genuity, and Cantor Fitzgerald have initiated Atai Life Sciences ([[ATAI]] +2.3%) with buy/overweight ratings. Credit Suisse has a $25 price target on shares (~35% upside) Credit...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 17, 2021 – What was once a war on drugs has turned into a public push for the decriminalization and legalization of illegal drugs with potential therapeutic benefits. Leg...
BERLIN, Germany, July 07, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that it will present and p...
Palm Beach, FL – July 7, 2021 – Psychedelic drugs and therapies are truly becoming mainstream and are expected to become even more so in the years to come. Psychedelic drugs involve various types of chemical substances including LSD and chemical extracted from plants. Psychede...
Mental illnesses are tough to treat, and modern medicine can't guarantee relief for many patients. New therapies derived from psychedelic compounds, however, are offering hope, not to mention a slew of opportunities for forward-thinking investors. Since ATAI Life Sciences' (NASDAQ...
NetworkNewsWire Editorial Coverage : In May 2013, GW Pharma listed on Nasdaq, selling 3.5 million shares at $8.90 each to investors betting that GW was charting a profitable course as a biotech developing new drugs from cannabis-derived compounds. Legal cannabis was only beginning to gain...
Mushrooms seem to be popping up everywhere these days. All as millions digest the idea that mushrooms can support immune systems, reduce inflammation, and help improve moods. Chaga for example has even caught the attention to coffee drinkers, says Thrillist. " It's a superfood said to preve...
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
ATAI Life Sciences N.V. Website:
Alcohol use disorder is a disorder characterized by an inability to stop or control one’s drinking despite adverse health, occupational or social consequences. Conventional treatments include medication, behavioral therapy, and support groups. Even with these treatments, however, many ind...
Psychedelics such as DMT, LSD and psilocybin have demonstrated promise in the treatment of affective symptoms of a range of disorders. These drugs work by inducing an altered state of consciousness , which includes intensified perceptions and emotions, which have been associated with therapeutic...